Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1715
    +0.0021 (+0.18%)
     
  • GBP/USD

    1.2623
    +0.0000 (+0.00%)
     
  • Bitcoin GBP

    55,355.12
    -566.94 (-1.01%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

U.S. FDA places partial hold on AstraZeneca cancer drug trials

LONDON, Oct (HKSE: 3366-OL.HK - news) 27 (Reuters) - U.S. health authorities have placed a partial clinical hold on the enrolment of new patients with head and neck cancer into studies involving AstraZeneca (NYSE: AZN - news) 's big new drug hope durvalumab, the company said on Thursday.

The drugmaker said the Food and Drug Administration action related only to head and neck cancer, adding that trials were continuing with existing patients. Trials of the immunotherapy drug in different cancer types are also progressing as planned. (Reporting by Ben Hirschler; Editing by Martinne Geller)